SCHEMBL10199428

SCHEMBL10199428

Cc1nccc(-c2ccccc2)c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.58
CHEK1 O14757 1/20 0.47
PDCD1 Q15116 3/20 0.43
CD274 Q9NZQ7 3/20 0.43
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43
DAPK3 O43293 1/20 0.43
JAK2 O60674 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
IGF1R P08069 1/20 0.43
FGFR1 P11362 1/20 0.43
PRKACA P17612 1/20 0.43
FLT1 P17948 1/20 0.43
LTK P29376 1/20 0.43
GRK5 P34947 1/20 0.43
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27546357 0.83 GRM4 (0.46) GRM4CDK8LRRK2AURKBL3MBTL1
Hydrochloric Acid SCHEMBL27470087 0.81 GRM4 (0.45) GRM4CDK8LRRK2AURKBCYP1A2
SCHEMBL11606622 0.81 CHEK1 (0.46) GRM4CHEK1PDCD1CD274IKBKB
SCHEMBL6516685 0.81 CHEK1 (0.46) GRM4CHEK1IKBKBCHUKDAPK3
Iodide SCHEMBL31070281 0.81 GRM4 (0.45) GRM4CDK8LRRK2AURKBL3MBTL1
SCHEMBL15865503 0.81 NOS3 (0.54) GRM4CHEK1PDCD1CD274IKBKB
Hydrochloric Acid SCHEMBL29628896 0.81 GRM4 (0.45) GRM4CDK8LRRK2AURKBCYP1A2
Iodide SCHEMBL9618573 0.81 GRM4 (0.45) GRM4CDK8LRRK2AURKBL3MBTL1
SCHEMBL10199363 0.80 CYP2A6 (0.50) GRM4ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL12765339 0.79 CHEK1 (0.45) GRM4CHEK1PDCD1CD274IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108358834-A A kind of polysubstituted pyridine derivative and preparation method thereof 兰州大学 2018-08-03 CN disclosed
US-20150238506-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-08-27 US disclosed
US-20150238506-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-08-27 US disclosed
US-9079907-B2 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-07-14 US disclosed
US-9079907-B2 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-07-14 US disclosed
EP-2742936-A1 Fused heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (JP) 2014-06-18 EP disclosed
EP-2727585-A1 In-vivo screening method Takeda Pharmaceutical Company Limited (JP) 2014-05-07 EP disclosed
US-20120165312-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SHIRAI JUNYA (JP) 2012-06-28 US disclosed
US-20120165312-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SHIRAI JUNYA (JP) 2012-06-28 US disclosed
US-8158617-B2 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-17 US disclosed
US-8158617-B2 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-17 US disclosed
US-20100144741-A1 ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS FREDERIKSEN MATHIAS 2010-06-10 US disclosed
US-20100144741-A1 ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS FREDERIKSEN MATHIAS 2010-06-10 US disclosed
US-20090131402-A1 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-05-21 US disclosed
US-20090131402-A1 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-05-21 US disclosed
EP-2018863-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165312-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF HTR2C, HTR3C, HTR3B GRM4 88/4885CHEK1 3905/4885PDCD1 4858/4885
US-20090131402-A1 Fused heterocyclic compound and use thereof HTR2C, HTR3C, HTR3B GRM4 88/4885CHEK1 3905/4885PDCD1 4858/4885
US-20100144741-A1 ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS BACE1, BACE2, APP GRM4 1591/4885CHEK1 3534/4885PDCD1 1390/4885
US-20150238506-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF HTR2C, HTR3C, HTR3B GRM4 88/4885CHEK1 3905/4885PDCD1 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.